Pathophysiology News and Research

RSS

Clinicians should specify subtypes of depression and combine antidepressants and psychotherapy

It is unlikely that different types of depression can be combined to one single disease called Major Depression. When testing the efficacy of antidepressants or psychotherapy, clinicians should make an attempt to specify the subtypes of depression and to combine antidepressants and psychotherapy in a sequential approach.

7 Dec 2010

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology, to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.

7 Dec 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

6 Dec 2010

MRS imaging technique may help diagnose chronic traumatic encephalopathy

In a study of ex-pro athletes, researchers found that a specialized imaging technique called magnetic resonance spectroscopy (MRS) may help diagnose chronic traumatic encephalopathy (CTE), a disorder caused by repetitive head trauma that currently can only be definitively diagnosed at autopsy. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

Military surgeons provide guidance on handling emergency blast injuries

Hospitals all over the world need to be aware of how to treat emergency blast injuries and military surgeons can provide valuable knowledge and advice to their civilian counterparts based on their experience of battlefield injuries. That is the driving force behind two papers published online by BJS, the British Journal of Surgery.

22 Nov 2010

New findings identify Sortilin as a potential therapeutic site to alter PGRN pathology in dementia

Frontotemporal lobar degeneration (FTLD) refers to a group of disorders associated with degeneration of the frontal and temporal lobes of the brain. Symptoms include dementia, aphasia, and semantic disorders.

18 Nov 2010

Journal of Alzheimer's Disease highlights latest scientific studies of AD

A supplement to the Journal of Alzheimer's Disease on "Anesthetics and Alzheimer's Disease" provides the platform to bring the latest scientific studies to the AD research and clinical communities.

15 Nov 2010

InfraReDx to present LipiScan scientific abstracts at AHA 2010

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the upcoming presentation of three LipiScan-related scientific abstracts at the American Heart Association Scientific Sessions 2010 (AHA 2010), being held Nov. 13-17, 2010 at McCormick Place in Chicago.

15 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia

9 Nov 2010

Research on immune system may help in healing chronic inflammatory diseases

Biochemists at Kiel University, along with international scientists, have identified an important messenger in the immune system. The messenger interleukin-27 plays an important role when the human body blocks inflammations.

9 Nov 2010

Diverse Surgeons Initiative addresses lack of minority surgeons in academic field

According to a report published in the October issue of the Journal of the American College of Surgeons, a grant-funded program tailored to provide advanced minimally invasive surgery skills to young, underrepresented minority surgeons, is helping address shortages of minority faculty members at US medical institutions.

3 Nov 2010

Molecular imaging technique pinpoints changes that take place in injured brain

Results from a study published in the November issue of The Journal of Nuclear Medicine (JNM) show that powerful imaging techniques positron emission tomography (PET) fused with magnetic resonance imaging (MRI) are helping researchers better understand the long-term functional and structural changes that take place after traumatic brain injury (TBI).

2 Nov 2010

PFF’s national scientific conference improves clinical understanding of IPF

The Pulmonary Fibrosis Foundation (PFF) today announced that it is establishing a national scientific conference for idiopathic pulmonary fibrosis (IPF) physicians and patients beginning in 2011. IPF Summit 2011 From Bench to Bedside, will be held at the Marriott Magnificent Mile in Chicago, IL on December 1-3, 2011.

28 Oct 2010

Researcher hopes to provide effective medication for Parkinson's disease

The side effects of the standard medication for Parkinson's disease have long been a preoccupation of brain researchers. Now Daniella Rylander has presented new findings in a recently defended PhD thesis at Lund University that provide hope of more effective medication for those who suffer from the nerve cell disease.

21 Oct 2010

Elsevier announces publication of 2010 ERC Guidelines in Resuscitation journal

Elsevier announces the publication of the 2010 European Resuscitation Council (ERC) Guidelines in the journal Resuscitation. These guidelines are based on an extensive international review of all the science supporting cardiopulmonary resuscitation (CPR), the 2010 International Consensus on CPR Science, which is also published in the current issue of Resuscitation. This year is the 50th anniversary of CPR.

19 Oct 2010

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Salix Pharmaceuticals, Ltd. today announced the presentation of two analyses of data from its Phase 3 pivotal clinical trials, TARGET 1 and 2, demonstrating a 14-day course of XIFAXAN 550 mg (rifaximin) taken three times daily achieved adequate relief of symptoms of non-constipation irritable bowel syndrome (non-C IBS) in a significantly greater proportion of patients compared with placebo.